Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its ...

Summary by Post Register
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital

3 Articles

Post RegisterPost Register
Center

Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its ...

BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital

Read Full Article
Caledon EnterpriseCaledon Enterprise
Reposted by
Muskoka RegionMuskoka Region
Lean Left

Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital

·Caledon, Canada
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Left
67% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Caledon Enterprise broke the news in Caledon, Canada on Thursday, September 4, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Idaho Falls icon

Idaho Falls

Muskoka icon

Muskoka

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal